Project: First multi-modal liquid biopsy IVD to predict response to immune checkpoint inhibitors in cancer
| Acronym | PRECISE (Reference Number: 114908) |
| Duration | 01/04/2021 - 01/01/2024 |
| Project Topic | The project will deliver a novel in vitro diagnostic (IVD) liquid biopsy test service for accurate immune checkpoint inhibitor (ICI) response prediction in bladder cancer (BC) patients. A unique multi-omics approach is developed combining mRNA and kinase activity profiling using proprietary AI-driven algorithms. The IVD will enter pivotal clinical trials 6 months after the project for clinical validation of our multi-modality approach and is expected to enter the market as a CE-IVD by 2026. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Novigenix SA | Coordinator | Switzerland |
| 2 | PamGene International B.V. | Partner | Netherlands |
| 3 | Radboud University Medical Center | Partner | Netherlands |